Stay updated on Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The Locations section was updated to show 11 locations, and the Miami Cancer Institute site was removed from the list.
    Difference
    0.4%
    Check dated 2026-01-08T01:37:33.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Study Record Dates show additions of newer date entries (e.g., 2025-12-31 and 2025-12-29) and removals of earlier timestamps (e.g., 2025-09-09 and 2025-09-08).
    Difference
    0.3%
    Check dated 2025-12-31T17:55:26.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The study Locations section now lists Connecticut, Florida, Indiana, New Jersey, New York, Pennsylvania, and Vermont as sites. A new revision note v3.3.3 appears on the page, and the HHS Vulnerability Disclosure footer link has been removed.
    Difference
    0.8%
    Check dated 2025-12-24T14:40:07.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    43 days ago
    Change Detected
    Summary
    The update shows a minor revision from v3.3.1 to v3.3.2. No substantive study content or user-facing features appear to be affected.
    Difference
    0.0%
    Check dated 2025-12-01T17:31:08.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    A new page revision label was added (v3.3.1) replacing the previous v3.2.0. There is no evident change to the study details, eligibility criteria, or outcomes in the visible content.
    Difference
    0.0%
    Check dated 2025-11-24T14:39:37.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The government funding lapse notice was removed from the page. It previously warned that information may not be up to date and that inquiries could be delayed.
    Difference
    0.3%
    Check dated 2025-11-17T06:52:39.000Z thumbnail image

Stay in the know with updates to Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.